Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer
Номер патента: EP4291564A1
Опубликовано: 20-12-2023
Автор(ы): Benoit Christian Albert Ghislain De Boeck, Frederik Jan Rita Rombouts, Soufyan JERHAOUI
Принадлежит: Janssen Pharmaceutica NV
Опубликовано: 20-12-2023
Автор(ы): Benoit Christian Albert Ghislain De Boeck, Frederik Jan Rita Rombouts, Soufyan JERHAOUI
Принадлежит: Janssen Pharmaceutica NV
Реферат: The present invention relates to compounds of formula (I) wherein XI is as myeloid cell leukemia-1 (MCL-1) inhibitors for the treatment of cancer, such as e.g. prostate, lung, pancreatic, breast, ovarian, and cervical cancer, melanoma, B-cell chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). An exemplary compound is e.g. compound 1
Macrocyclic 1,3-bridged 6-chloro-7-pyrazol-4-yl-1h-indole-2-carboxylate and 6-chloro-7-pyrimidin-5-yl-1h-indole-2-carboxylate derivatives as mcl-1 inhibitors for the treatment of cancer
Номер патента: AU2022220818A1. Автор: Frederik Jan Rita Rombouts,Benoit Christian Albert Ghislain De Boeck,Soufyan JERHAOUI. Владелец: Janssen Pharmaceutica NV. Дата публикации: 2023-09-28.